

Holdings. RFAAX 1, at 4. That location has been operating, and continues to operate, as a marijuana cultivation facility, growing both medical and recreational marijuana, which is sold to third-party marijuana dispensaries operating within Colorado's marijuana market. RFAAX 1, at 4.

IV. Discussion

Here, Applicant's parent company, MedPharm Holdings, and its sister company, MX, have been manufacturing marijuana without DEA registration for at least the past 10 years. RFAAX 1, at 4. Further, Applicant's parent company and sister company have been engaged in the manufacture of marijuana for sale in the recreational market. RFAAX 1, at 4. Manufacturing marijuana without a registration from DEA violates the CSA and DEA regulations. 21 U.S.C. 822(a)(1), 823(a), 841(a)(1); 21 CFR 1301.11(a); *Raich*, 545 U.S. at 12–13. Further, manufacturing marijuana for the recreational market violates the CSA and DEA regulations, and it constitutes diversion of a Schedule I controlled substance. 21 CFR 1301.13(k)(1)(iv), 1301.71(a), .72–.76, 1318.04(a); *Raich*, 545 U.S. at 12–13.

In sum, Applicant's corporate structure, acting through the company that owns and controls Applicant and its sister company, all of which are managed by the same CEO, Mr. A.G.,⁶ has engaged in the unregistered manufacture of marijuana for at least a decade and has diverted marijuana into the recreational market, in violation of federal law. *See* Sections III–IV. The unregistered manufacture of marijuana and the diversion of marijuana into recreational channels weigh against a finding of registration being consistent with the public interest and demonstrate a lack of “prior compliance with the” CSA and DEA regulations, which also weigh against a finding of registration being consistent with the public interest. 21 U.S.C. 823(a)(6); 21 CFR 1318.05(b)(1).

Considering the un rebutted and substantial evidence of record establishing Applicant's unregistered manufacture of and diversion of a Schedule I controlled substance, the Agency determines that issuing Applicant a manufacturer registration (bulk) for marijuana would not be

consistent with the public interest.⁷ 21 U.S.C. 823(a)(6); 21 CFR 1318.05(b)(1). Accordingly, the Agency will order the denial of Applicant's application for registration.⁸

Order

Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21 U.S.C. 823(a), I hereby deny the pending application for a DEA Certificate of Registration, Control No. W16089931E, submitted by MedPharm Research, LLC, as well as any other pending application of MedPharm Research, LLC, to amend or modify this application, or for additional registration in Colorado. This Order is effective November 6, 2026.

Signing Authority

This document of the Drug Enforcement Administration was signed on October 2, 2026, by DEA Administrator Terrance C. Cole. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters

⁷ The burden is on the applicant to establish that its registration is consistent with the public interest. 21 CFR 1301.44(a); 21 CFR 1318.03(b); RFAAX 1, at 2. Here, by virtue of its default, Applicant has failed to present any evidence whatsoever to establish its registration is consistent with the public interest, and the deemed admitted facts (*i.e.*, noncompliance with the CSA, violation of the registration requirement, and diversion of a Schedule I controlled substance), weigh against a finding in favor of registration. Although these are only factors, they are dispositive here because Applicant's default means it not only waived the right to present evidence regarding these factors, but it also waived the right to present any other evidence that its registration would be consistent with the public interest.

⁸ Denial of Applicant's application in this Order does not prohibit Applicant from submitting an application through the new framework established for issuing registrations based on state licenses to handle marijuana for medical purposes, if applicable. *See Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements*, 91 FR 22714, 22721 (2026) (adding paragraph (k) to 21 CFR 1301.13 “establish[ing] an expedited review process for entities holding state medical marijuana licenses who seek registration as a marijuana manufacturer”); *see also id.* at 22722 (adding paragraphs (g)(2)–(4) to 21 CFR 1308.13 placing into Schedule III marijuana, marijuana extract, and delta-9-tetrahydrocannabinols “subject to a state medical marijuana license”).

the legal effect of this document upon publication in the **Federal Register**.

Heather Achbach,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2026–20553 Filed 10–6–26; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

[OMB Number 1110–0052]

Agency Information Collection Activities; Proposed eCollection eComments Requested; Title—Identity History Summary Request Form (1–783)

AGENCY: Criminal Justice Information Services (CJIS) Division, Federal Bureau of Investigation (FBI), Department of Justice (DOJ).

ACTION: 30-Day notice.

SUMMARY: The CJIS, FBI, DOJ will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the **Federal Register** on August 5, 2026, 91 FR 50558, allowing a 60-day comment period.

DATES: Comments are encouraged and will be accepted for 30 days until November 5, 2026.

FOR FURTHER INFORMATION CONTACT: If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Brian A. Cain, 1000 Custer Hollow Road, Clarksburg, WV 26306, 304–625–CJIS, bacain@fbi.gov.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

⁶ *See Pharmboy Ventures Unlimited, Inc.*, 77 FR 33770, 33771 n.2 (2012) (noting that “DEA has long held that” the Agency “can look behind [an entity's] ownership structure” to evaluate the conduct of the people making decisions regarding the controlled substance side of the business) (citing *Carriage Apothecary*, 52 FR 27599, 27599 (1987)).

- Enhance the quality, utility, and clarity of the information to be collected; and/or
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function and entering either the title of the information collection or the OMB Control Number 1110–0070. This information collection request may be viewed at www.reginfo.gov. Follow the instructions to view Department of Justice, information collections currently under review by OMB. If you submit a comment, please send a copy to Brian Cain to bacain@fbi.gov.

DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.

Abstract: Individuals interested in obtaining a copy of their identification record contained in the FBI’s Next Generation Identification System. The U.S. Department of Justice Order 556–773 directs the FBI to publish rules for the dissemination of arrest and conviction records to the subjects of such records upon request. This order resulted in a determination that 28 United States Code 534 does not prohibit the subjects of arrest and convictions records from having access to those records.

Overview of This Information Collection

1. *Type of Information Collection:* Revision of a currently approved collection Title of the Form/Collection: Identity History Summary Request Form (1–783).

2. *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* 1110–0052, Form Identity History Summary Request (1–783); CJIS Division, FBI, DOJ.

3. *Affected public who will be asked or required to respond, as well as a brief abstract:* Affected Public: Individuals; Individuals wishing to obtain a copy of their identification record based on US DOJ Order 556–773.

4. *Obligation to Respond:* Required to obtain or retain a benefit.

5. *Total Estimated Number of Respondents:* 74,438 per year.

6. *Estimated Time per Respondent:* 5 minutes.

7. *Frequency:* Varies.

8. *Total Estimated Annual Time Burden:* 6,203 hours.

9. *Total Estimated Annual Other Costs Burden:* \$27.72 avg hourly wage × 6,203 hours = \$171,947.00 cost burden.

If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Enterprise Portfolio Management, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W–218 Washington, DC 20530.

Dated: October 5, 2026.

Darwin Arceo,

Department Clearance Officer for PRA, U.S. Department of Justice.

[FR Doc. 2026–20534 Filed 10–6–26; 8:45 am]

BILLING CODE 4410–02–P

DEPARTMENT OF JUSTICE

[CPCLO Order No. 010–2026]

Privacy Act of 1974; System of Records

AGENCY: Drug Enforcement Administration, United States Department of Justice.

ACTION: Notice of a modified system of records.

SUMMARY: Pursuant to the Privacy Act of 1974, and Office of Management and Budget (OMB) Circular No. A–108, notice is hereby given that the Drug Enforcement Administration (DEA), a component of the United States Department of Justice (Department or DOJ), proposes to modify and republish a system of records notice titled “JUSTICE/DEA–021, DEA Aviation Unit Reporting System,” 65 FR 24986, to be retitled “DEA Aviation Division Reporting System”, which is the repository of reporting records held by DEA’s Aviation Division. DEA proposes to update the categories of individuals covered by the system, as well as record categories, purpose of the system, routine uses of records maintained in the system and policies and practices for storing, retrieving, retaining, and disposing of records in the system.

DATES: In accordance with 5 U.S.C. 552a(e)(4) and (11), this notice is effective upon publication, subject to a 30-day period in which the public may comment on the routine uses described below. Therefore, please submit any comments by November 5, 2026.

ADDRESSES: The public, Office of Management and Budget, and Congress are invited to submit any comments online via the Federal e-Rulemaking Portal: <http://www.regulations.gov> and following the instructions for submitting comments; by mail to the United States Department of Justice, ATTN: Privacy Analyst, Office of Privacy and Civil Liberties, Two Constitution Square (2CON), 145 N Street NE, Suite 8W.300, Washington, DC 20530, by facsimile at 202–307–0693, or by email at privacy.compliance@usdoj.gov. To ensure proper handling, please reference the above CPCLO Order No. on your correspondence.

FOR FURTHER INFORMATION CONTACT: David Makoto Hudson, Attorney, Drug Enforcement Administration, Office of Chief Counsel, Strategic Programs Section, 8701 Morrisette Drive, Springfield, VA 22152.

SUPPLEMENTARY INFORMATION: DEA is proposing to modify this system to update the categories of individuals covered by the system. More specifically, the modification will reflect that the categories of individuals covered by the system include DEA employees and contractors and not just DEA pilots, as well as vendors, detainees, inmates, non-DEA law enforcement personnel, and other federal government employees and contractors. Additional changes are being made to this Notice to provide greater clarity about the information contained in the Inspection Division Records and the types of information that can be retrieved. The DEA also proposes to update, add to, and/or clarify the system location, the categories of individuals covered by the system; the record categories in the system; the record source categories; the purpose of the system; the system’s routine uses; policies and practices for storing, retrieving, retaining, and disposing of records in the system; the record access procedures; and procedures to contest the accuracy of records in the system. The purpose of this modification is to update the language to better reflect the modernization of applications in DEA’s information system related to controlled substance transaction reporting and to more accurately describe the breadth of the records contained therein. Finally, the modification will bring the SORN